Cramer said Regeneron remains one of his favorite biotech stocks.
Off the Charts
In the "Off The Charts" segment, Cramer went head to head with colleague Tim Collins over the chart of Pfizer ( PFE), a boring Big Pharma name that might just be getting a little more exciting in 2013. According to Collins' research, the daily chart of Pfizer is displaying the bullish reverse head-and-shoulders pattern, with the left shoulder in October, the head in November and the right shoulder in December. Collins said based on this pattern, Pfizer could see a 6% move in the short term and more over the next six months. This trend was confirmed by the TRIX momentum indicator. Pfizer's weekly chart also was bullish, noted Collins, with the stock trading sideways during the first half of 2012, only to enter a bullish channel during the back half of 2012. Currently the stock is consolidating again and Collins thinks the uptrend is not far away. Cramer said he's already on record as saying Pfizer could repeat its 15% gain from last year. He said that's big news for a sleepy stock like Pfizer that lets invests sleep enough and offers a big dividend yield to boot.
In the Lightning Round, Cramer was bullish on Lumber Liquidators ( LL), Home Depot ( HD), Alpha Natural Resources ( ANR), Invesco Mortgage Capital ( IVR) and Annaly Capital ( NLY). Cramer was bearish on Exelon ( EXC), Lowe's ( LOW) and Questcor Pharmaceuticals ( QCOR).
In his second "Executive Decision" segment, Cramer spoke with Dr. George Scangos, CEO of Biogen Idec ( BIIB), another biotech company presenting this week at JPMorgan's annual health-care conference. Scangos started off by updating investors on his company's treatments for muscular sclerosis. He said Biogen's two current injectable treatments are doing very well and his company expects approval of BG12, a new oral medication for the disease, possibly as early as March of this year. When asked whether the new pill could cannibalize the injectable treatments, Scangos said many patients are happy with their current treatments and have their disease under control, so there will be little incentive to switch. Scangos continued that all three of Biogen's MS drugs treat different segments of the population and he's delighted to have three options for patients. He was also upbeat about his company's two new hemophilia drugs, which will allow patients to inject themselves less frequently. He said those drugs will provide a great service to patients.